Home | Welcome to Contract Pharma   
Last Updated Wednesday, July 30 2014
Print

Financial Reports: Covance



By Gil Roth



Published February 5, 2014
Related Searches: Toxicology Development
Covance 4Q13

4Q Net Revenues: $623 million (+11%)

4Q Earnings: $36 million (+35%)

FY Net Revenues: $2.4 billion (+10%)

FY Earnings: $179 million (+89%)

Comments: Late-Stage Development revenues grew 15% in 4Q to $395 million, led by 17% growth in central laboratories and 13% growth in clinical development. FY revenues in Late-Stage Development were up 17% to $1.5 billion. Early Development revenues grew 5% in 4Q to $228 million, led by growth in clinical pharmacology and toxicology. For FY, Early Development revenues were flat at $871 million. The company cited discovery support and "certain pharmaceutical chemistry services" as areas of decline during the period.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On